Related trials
		 
			
				 
				
					SPIRIT IV, 2010 - everolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					BASKET-PROVE (SES), 2010 - sirolimus eluting stent  vs bare-metal stent
				
			 
			
				 
				
					GISSOC II, 2010 - sirolimus eluting stent  vs bare-metal stent
				
			 
			
				 
				
					SORT-OUT-3, 2010 - zotarolimus eluting stent  vs sirolimus eluting stent
				
			 
			
				 
				
					RESOLUTE, 2010 - zotarolimus eluting stent  vs everolimus eluting stent
				
			 
			
				 
				
					BASKET-PROVE (EES), 2010 - everolimus eluting stent  vs bare-metal stent
				
			 
			
				 
				
					TRIANA, 2009 - primary ballon angioplasty  vs tenecteplase
				
			 
			
				 
				
					DEBATER (SES vs BMS), 2009 - sirolimus eluting stent  vs bare-metal stent
				
			 
			
				 
				
					ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol eluting stent  vs sirolimus eluting stent
				
			 
			
				 
				
					ZEST (vs PES), 2009 - zotarolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					ISAR-LEFT-MAIN, 2009 - sirolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					NORDISTEMI, 2009 - thrombolysis + angioplasty  vs immediate thrombolysis
				
			 
			
				 
				
					ISAR TEST 3 (BP), 2009 - sirolimus biodegradable polymer  vs sirolimus eluting stent
				
			 
			
				 
				
					COMPARE, 2009 - everolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					ENDEAVOR IV, 2009 - zotarolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					Juwana, 2009 - sirolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					GENIUS-STEMI, 2009 - Genous stent  vs bare-metal stent
				
			 
			
				 
				
					ZEST AMI (vs PES), 2009 - zotarolimus eluting stent  vs paclitaxel eluting stent
				
			 
			
				 
				
					ISAR-TEST-4 (biodegradable polymer), 2009 - sirolimus biodegradable polymer  vs sirolimus eluting stent
				
			 
			
				 
				
					ZEST (vs SES), 2009 - zotarolimus eluting stent  vs sirolimus eluting stent
				
			 
			
				 
				
					PASEO, 2009 - drug-eluting stents  vs bare-metal stent
				
			 
			
				 
				
					ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent  vs sirolimus eluting stent
				
			 
			
				 
				
					ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol eluting stent  vs zotarolimus eluting stent
				
			 
			
				 
				
					Thiele, 2009 - sirolimus ES  vs MIDCAB
				
			 
			
				 
				
					ZEST AMI (vs SES), 2009 - zotarolimus eluting stent  vs sirolimus eluting stent
				
			 
		 
		 
		 
		
		See also:
		 
			
				
					All coronary artery disease clinical trials
				
			
			
				
					All acute myocardial infarction clinical trials
				
			
		
			
			All clinical trials of PCI
			
		
		
			
			All clinical trials of drug-eluting stents
			
		
	 | 
	
		 
	 | 
	
	Treatments
	
	
		| Studied treatment | 
		
		paclitaxel-eluting stents and sirolimus-eluting stents
		 
		
		
		 | 
	 
	
		| Control treatment | 
		
		bare metal stent
		 
		
		
		 | 
	 
		
			| Concomittant treatment | 
			aspirin, clopidogrel 300 mg, unfractionated heparin 70 U/kg, upstream glycoprotein IIb/IIIa inhibitor. | 
		 
		
			| Remarks | 
			3 arms : SES, PES, BM | 
		 
	 
	
	
	
	Patients
	
		
			| Patients | 
			patients with ST-elevation myocardial infarction within 12 hours from symptom onset | 
		 
		
			| Exclusion criteria | 
			active internal bleeding or bleeding disorder within the last month; history of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm; allergy to one of the study medications; history of stroke within the last month; history of surgical procedure or trauma within the last month; aortic dissection; fibrinolytic therapy within the previous 24 hours; thrombocytopenia; hemorrhagic retinopathy; currently taking warfarin; pregnancy
 | 
		 
				| Baseline characteristics | 
					
					
						
							| age | 
							62 y  | 
						 
						
							| diabetes (%) | 
							26%  | 
						 
						
							| Female (%) | 
							29%  | 
						 
						
							| STEMI | 
							100%  | 
						 
					 						
					 | 
				 
	 
	
	
	
	
	
	
	Method and design
	
	
		| Randomized effectives | 
		180 / 90 (studied vs. control) | 
	 
		
			| Design | 
			Parallel groups | 
		 
		
			| Blinding | 
			open | 
		 
		
			| Follow-up duration | 
			4.3 years | 
		 
		
			| Lost to follow-up | 
			0% | 
		 
		
			| Primary endpoint | 
			TLR 1 year | 
		 
	
	 
	
	
	
	
	
	
	
  
	Results	
	
		
			No results available for this trial
			 - no clinical endpoint reported 
		 
Meta-analysis of all similar trials: 
			
				
					Drug eluting stent in coronary artery disease for all type of patients
				
			 
			
				
					Drug eluting stent in coronary artery disease for acute myocardial infarction
				
			 
			
				
					myocardial revascularization in acute myocardial infarction for all type of patients
				
			 
			
				
					PCI in acute myocardial infarction for all type of patients
				
			 
	
  
	
	
	
	
	
	
	
	
	
	
	
		 
		Reference(s)
	
	
	
			- 
				
			    Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G. 
			    The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial..
			    JACC Cardiovasc Interv 2009 Jun;2:515-23
			    
 
				
					 
					Pubmed
				 	
				|
				
					Hubmed
				
				| Fulltext
		 
		
			- 
				
			    Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G. 
			    Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial..
			    Circulation 2009;120:964-72
			    
 
				
					 
					Pubmed
				 	
				|
				
					Hubmed
				
				| Fulltext
		 
		
	 	
			 
			
			
			 
 |